CLS sponsors Affinity Proteomics 2017

Clinical Laserthermia Systems (CLS) (publ), will be a sponsor of the Alpbach Affinity Proteomics Workshop in March 2017. The Affinity Proteomics Workshop, being held for the seventh time, is a meeting at which the latest research on antibodies and other protein- binding molecules and their role in cells and tissues are discussed. The meeting will be held 13-15 March 2017 and will include presentations, publications and scientific posters. The Alpbach Affinity Proteomics Workshop brings together prominent Key Opinion Leaders, primarily in the field of cancer research. 

“Affinity Proteomics offers a path into a network to which CLS has not previously had significant access. We know we can augment and broaden our expertise here,” says CEO Lars-Erik Eriksson, CLS. 

Proteomics concentrates on protein analysis and identification: what the proteins produced by an organism look like and how they function, work together and behave. The methodology makes it possible to study the changes at the protein level that arise upon activation of the immune response, which is one of the aims of imILT. 

Carl Borrebaeck, professor at the Department of Immunotechology at Lund University and a director of companies including CLS, will be one of the speakers at Affinity Proteomics. 

More information about the Alpbach Affinity Proteomics Workshop: www.affinityproteomicsalpbach.com 

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Aktietorget under the stock symbol CLS B. More information is available on the Company's website www.clinicallaser.se